Taylor & Francis Group
Browse
1/1
2 files

Identification of 20 novel loci associated with ischaemic stroke. Epigenome-wide association study

Version 3 2020-05-03, 14:17
Version 2 2020-04-06, 14:53
Version 1 2020-03-23, 09:47
dataset
posted on 2020-05-03, 14:17 authored by Carolina Soriano-Tárraga, Uxue Lazcano, Eva Giralt-Steinhauer, Carla Avellaneda-Gómez, Ángel Ois, Ana Rodríguez-Campello, Elisa Cuadrado-Godia, Alejandra Gómez-González, Alba Fernández-Sanlés, Roberto Elosua, Israel Fernández-Cadenas, Natalia Cullell, Joan Montaner, Sebastian Moran, Manel Esteller, Jordi Jiménez-Conde, Jaume Roquer

DNA methylation is dynamic, varies throughout the life course, and its levels are influenced by lifestyle and environmental factors, as well as by genetic variation. The leading genetic variants at stroke risk loci identified to date explain roughly 1–2% of stroke heritability. Most of these single nucleotide polymorphisms are situated within a regulatory sequence marked by DNase I hypersensitivity sites, which would indicate involvement of an epigenetic mechanism. To detect epigenetic variants associated with stroke occurrence and stroke subtypes.

A two-stage case–control epigenome-wide association study was designed. The discovery sample with 401 samples included 218 ischaemic stroke (IS) patients, assessed at Hospital del Mar (Barcelona, Spain) and 183 controls from the REGICOR cohort. In two independent samples (N = 226 and N = 166), we replicated 22 CpG sites differentially methylated in IS in 21 loci, including 2 CpGs in locus ZFHX3, which includes known genetic variants associated with stroke. The pathways associated with these loci are inflammation and angiogenesis. The meta-analysis identified 384 differentially methylated CpGs, including loci of known stroke and vascular risk genetic variants, enriched by loci involved in lipid metabolism, adipogenesis, circadian clock, and glycolysis pathways.

We identified a set of 22 CpGs in 21 loci associated with IS. Our analysis suggests that DNA methylation changes may contribute to orchestrating gene expression that contributes to IS.

Funding

This project was funded in part by the following sources: Agència de Gestió Ajuts Universitaris de Recerca (2014 SGR 1213; 2017 SGR 222; PERIS SLT002/16/00088); Spain’s Ministry of Health (Ministerio de Sanidad y Consumo) through the Carlos III Health Institute (ISCIII-FIS-FEDER-ERDF, PI12/01238, PI15/00451, PI15/0044, PI15/00051, PI18/00017, PI17/02089, PI18/01338, CIBERCV); INVICTUS-PLUS, Instituto de Salud Carlos III RETIC (RD16/0019/0002); and a RecerCaixa 2013 research grant (JJ086116). Fundació la Marató TV3 (76/C/2011). A. Fernández-Sanlés was funded by the Spanish Ministry of Economy and Competitiveness (BES-2014–069718). Epigenisis and Maestro projects.

History